References

Teclistamab in relapsed or refractory multiple myeloma

10.1056/nejmoa2203478 · 2022 · External reference

Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma

10.1182/bloodadvances.2024013461 · 2024 · External reference

Safety and efficacy of teclistamab in patients with relapsed/refractory multiple myeloma: a real-world experience

10.1016/j.jtct.2023.12.016 · 2024 · External reference

Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study

10.1016/j.cmi.2024.02.023 · 2024 · External reference

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study

10.1038/s41408-024-01003-z · 2024 · External reference

Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study

10.1002/cncr.35107 · 2024 · External reference

High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network

10.1111/tid.12162 · 2014 · External reference

Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation

10.1016/j.jcv.2017.08.006 · 2017 · External reference

Cytomegalovirus (CMV) reactivation and CMV-specific cell-mediated immunity after chimeric antigen receptor T-cell therapy

10.1093/cid/ciad708 · 2024 · External reference

Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis

10.1182/bloodadvances.2022009435 · 2023 · External reference

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

10.1038/s41408-023-00879-7 · 2023 · External reference

Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the transplant associated virus infections forum

10.1093/cid/ciae321 · 2024 · External reference

Risk of infections in multiple myeloma patients treated with bispecific antibodies

10.1182/blood-2024-206155 · 2024 · External reference

Absolute lymphocyte count thresholds: a simple, readily available tool to predict the risk of cytomegalovirus infection after transplantation

10.1093/ofid/ofy230 · 2018 · External reference

T-cell characteristics impact response and resistance to T-cell-redirecting bispecific antibodies in multiple myeloma

10.1158/1078-0432.ccr-23-3333 · 2024 · External reference